Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Thomas Wiesel Cut Forest Labs


Thomas Weisel cut Forest Laboratories (FRX) to peer perform from outperform.

Analyst Donald Ellis said news of a failed milnacipran trial calls into question the company's future growth prospects absent significant acquisitions. He noted that he'd anticipated approval based on positive Phase II results, and was looking to milnacipran as the next potential blockbuster drug that would reinvigorate the company's growth. He believes the current premium is unwarranted given the absence of a late-stage R&D pipeline, slowing revenue, earnings growth, and minimal visibility of near-term positive catalysts. He sees 53 cents in earnings per share in the second quarter on $762.2 million in revenue and $2.35 fiscal year 2006 (ending March) earnings per share on $3.17 billion revenue.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus